Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vicore Pharma Holding AB ( (SE:VICO) ) has shared an update.
Vicore Pharma Holding AB has announced an increase in its number of shares and votes following a directed share issue, raising approximately USD 48 million. This development increases the company’s share capital and strengthens its financial position, potentially enhancing its ability to advance its drug development programs and maintain its competitive edge in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), for treating respiratory and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Their leading program, buloxibutid, is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
Average Trading Volume: 634,858
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.4B
For detailed information about VICO stock, go to TipRanks’ Stock Analysis page.